Top
image credit: Unsplash

Coronavirus company news summary – BioGX’s Covid-19 tests identify Omicron variant of SARS-CoV-2 virus – Sorrento’s partner orders COVISTIX tests for launch in Brazil

December 7, 2021

Category:

BioGX has reported that its portfolio of Covid-19 tests that work on the nucleocapsid (N-gene) and envelope (E-gene) can identify the Omicron variant of the SARS-CoV-2 virus. The company’s Covid-19 surveillance programme comprises complete in-silico assessment and investigational testing by researchers using sequences of ribonucleic acid (RNA) that bears viral mutations. BioGXn noted that its SARS-CoV-2 portfolio demonstrated the ability to identify all variants of interest and variants of concern, including the Omicron variant, in an analysis.

Read More on medicaldevice-network.com